If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACC.L Regulatory News (ACC)

  • There is currently no data for ACC

Pulsar update

6 Feb 2020 07:00

RNS Number : 1294C
Access Intelligence PLC
06 February 2020
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain for the purposes of MAR.

 

 

 

6th February 2020

ACCESS INTELLIGENCE PLC

Completion of Pulsar Accounting Review

Further to the announcement on 10 December 2019, the Board of Access Intelligence provides the following update following the completion of the review by an external firm of accountants of the accounts of the Pulsar business at closing.

In October 2019, Access Intelligence acquired the Pulsar business (comprising both Fenix Media Limited, which is incorporated in the UK, and Face US, which is incorporated in the US) from Cello Health plc ("Cello"). Following the identification of certain accounting questions on some contracts within Pulsar post acquisition, the Board of Access Intelligence commissioned an accounting review to be undertaken by independent accountants BDO.

Following completion of the BDO review, an adjustment of the previously disclosed unaudited financial results for Pulsar is required. Post this adjustment, for the year to 31 December 2018 Pulsar reported unaudited revenues of £6.8 million, gross profit of £3.8 million and an Adjusted EBITDA loss of £0.7 million. Upon acquisition by Access Intelligence, Pulsar's accounting reference period was amended. For the 11 month period to 30 November 2019, Pulsar would have had reported unaudited revenue of £5.2 million, gross profit of £2.3 million and an Adjusted EBITDA loss of £1.7 million.

Pursuant to the terms of the sale and purchase agreement signed on 2 October 2019 (the "Agreement"), and under the completion accounts reconciliation process agreed by both sides, Cello Health has agreed to pay Access Intelligence a net cash sum of £1.6m reflecting the shortfall in net assets delivered at closing versus the agreed target closing position.

In full and final settlement of any dispute under the Agreement regarding the appropriate valuation of the business, Cello Health has agreed that 4,076,238 of the consideration shares will be sold back to Access Intelligence for £1. As Access Intelligence currently does not have the requisite approvals to acquire these shares, a shareholder's meeting will be convened to obtain the necessary approval for the buy back. Upon completion of the buy back the relevant shares will be cancelled.

The post-acquisition contribution of Pulsar to Access Intelligence's consolidated financial results for the year to 30 November 2019 is expected to be revenue of £0.7 million, gross profit of £0.2 million and an Adjusted EBITDA loss of £0.5 million, prior to any acquisition accounting adjustments. The annual accounts may also be impacted by a potential non-cash write down. This is currently being discussed with the accountants and an update will be provided in due course.

This outcome of the financial analysis has no impact on the rationale for the Pulsar acquisition which is in line with a strategic ambition to strengthen capabilities in social media analysis, audience segmentation and social media marketing evaluation. Recurring revenues with Pulsar are around 70% of total revenue.

Related Party Transaction

Cello is a related party of the Company for the purposes of the AIM Rules by virtue of their status as substantial shareholders holding 10% or more or more of the Company's existing ordinary share capital.

The Board consider, having consulted with the Company's nominated adviser, finnCap, that the settlement with Cello set out above is fair and reasonable insofar as the Company's shareholders are concerned.

Commenting on the resolution of this matter, Joanna Arnold, CEO, said:

"Due to Cello Health's proactive engagement, we are pleased to have reached a swift and satisfactory resolution. The rationale for the acquisition remains unchanged and we look forward to growing the business as part of the Access Intelligence portfolio."

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

 

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance - Marc Milmo / Kate Bannatyne / Matthew Radley / Kate Washington

Corporate Broking - Alice Lane / Sunila de Silva

 

About Access Intelligence

 Access Intelligence PLC is a tech innovator, delivering high quality SaaS products that address the fundamental business needs of more than 3,500 global brands in the PR, communications and marketing industries. Listed on AIM, Access Intelligence provides technology that helps organisations understand what's important to their customers and their brand as they navigate a constantly changing world of politics, news and social media. This is alongside the practical tools and information to ensure their communications are relentlessly effective in building awareness, reputation and engagement.

 The expanding portfolio includes Vuelio, the platform that helps organisations make their stories matter; ResponseSource, a network that connects media and influencers to the resources they need, fast; and Pulsar, an audience insights and social listening platform.

 

- ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURSSIEEIESSESE
Date   Source Headline
19th Feb 20087:00 amRNSNotice of Results
7th Dec 20077:00 amRNSDirector/PDMR Shareholding
4th Dec 20077:01 amRNSTrading Statement
21st Nov 20077:00 amRNSDirector/PDMR Shareholding
9th Oct 20077:00 amRNSHolding(s) in Company
22nd Aug 200712:31 pmRNSDirector/PDMR Shareholding
16th Aug 20074:00 pmRNSWebsite Information
10th Aug 20077:00 amRNSDirector/PDMR Shareholding
9th Aug 20077:00 amRNSDirector/PDMR Shareholding
30th Jul 200712:02 pmRNSDirector/PDMR Shareholding
26th Jul 20077:01 amRNSInterim Results
10th Jul 20077:00 amRNSNotice of Results
18th Apr 20077:01 amRNSNew Contract Awarded
2nd Apr 20077:04 amRNSAccess Int targets NHS Trusts
15th Mar 20077:00 amPRNFinal Results
21st Feb 20077:01 amRNSNotice of Results
8th Jan 20077:00 amPRNTrading Statement
19th Dec 200611:39 amRNSVoting rights and capital
21st Nov 20067:01 amRNSDirector/PDMR Shareholding
2nd Nov 20061:11 pmRNSHolding(s) in Company
23rd Oct 20067:01 amRNSDirectors Share Purchases
16th Oct 200611:49 amRNSResult of EGM
20th Sep 20067:00 amPRN
1st Sep 20067:01 amRNSSenior Appointment
9th Aug 20063:41 pmRNSDirector/PDMR Shareholding
1st Aug 20067:02 amRNSInterim Results
25th Jul 20067:00 amRNSNotice of Interim Results
6th Jun 20061:41 pmRNSHolding(s) in Company
6th Jun 20061:40 pmRNSHolding(s) in Company
24th May 200612:33 pmRNSIssue of Equity
11th May 200611:28 amRNSIssue of Equity
10th May 20069:11 amRNSIssue of Equity - Amendment
8th May 20061:38 pmRNSIssue of Equity
9th Mar 20067:01 amRNSDirector/PDMR Shareholding
8th Mar 20067:00 amPRNFinal Results
13th Feb 20067:00 amRNSNotice of Results
2nd Dec 20057:00 amRNSTrading Statement
6th Oct 20056:17 pmRNSDirector/PDMR Shareholding
6th Jul 20057:00 amRNSInterim Results
6th Jul 20057:00 amRNSAcquisition
27th Jun 20054:26 pmRNSResult of EGM
27th Jun 20057:00 amRNSNotice of Results
14th Jun 20057:00 amRNSAGM Statement
2nd Jun 20055:46 pmRNSSch 1 - Access Intelligence
2nd Jun 20057:00 amRNSAcquisition
20th May 20057:00 amRNSABTA Partnership
15th Apr 20057:00 amRNSTrading Update
24th Feb 20057:01 amRNSFinal Results
7th Feb 20059:50 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.